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Background: Recent advances in deep digital sequencing have unveiled an unprecedented degree of clonal
heterogeneity within a single tumor DNA sample. Resolving such heterogeneity depends on accurate estimation of
fractions of alleles that harbor somatic mutations. Unlike substitutions or small indels, structural variants such as
deletions, duplications, inversions and translocations involve segments of DNAs and are potentially more accurate
for allele fraction estimations. However, no systematic method exists that can support such analysis.
Results: In this paper, we present a novel maximum-likelihood method that estimates allele fractions of structural
variants integratively from various forms of alignment signals. We develop a tool, BreakDown, to estimate the allele
fractions of most structural variants including medium size (from 1 kilobase to 1 megabase) deletions and duplications,
and balanced inversions and translocations.
Conclusions: Evaluation based on both simulated and real data indicates that our method systematically enables
structural variants for clonal heterogeneity analysis and can greatly enhance the characterization of genomically
instable tumors.
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Tumor development is driven by oncogenic alleles cre-
ated by somatic mutations [1]. These alleles are present
in a tumor sample at different fractions, resulting from a
history of clonal expansion [2]. Obtaining accurate esti-
mation of variant allele fractions (VAFs) has become a
critical step towards delineating the clonal architecture
of a tumor sample and identifying driver mutations that
promote clonal expansion [3-5].
Despite rapid progress in the next generation sequen-
cing (NGS), challenges remain in accurately estimating
VAFs. At a sequencing coverage of 50-100x, such as
those obtained from standard whole-genome sequencing
(WGS) or whole-exome sequencing, it is difficult to dis-
tinguish sub-clonal difference based on allele fractions
estimated from single nucleotide variants (SNVs) and
small indels [6]. At deeper (500-1000x) coverage, it is feas-
ible to distinguish a few clones [3-5,7]. Unfortunately,* Correspondence: kchen3@mdanderson.org
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genome scale is still prohibitively expensive. Even at such
high coverage, substantial variations in VAFs have been
observed among variants from the same clone, making it
challenging to infer the number of clones and assign vari-
ants to clones [8]. Megabase (Mb) long chromosomal ab-
errations have long been utilized in pathology laboratories
to characterize heterogeneity in a tumor sample [9]. Re-
cently, they have been utilized to perform early detection
in circulating cell-free DNA samples [10]. Industrial scale
application of paired-end short-insert NGS has made it
possible to extend such characterization to smaller SVs
that are of kilobase (Kb) in length [11]. Most NGS DNA
libraries have higher physical coverage than sequence
coverage, i.e., the DNA insert sizes are more than twice
longer than the read lengths. This makes structural vari-
ants (SVs), including small (Kb) SVs and balanced SVs,
more accurate targets than SNVs and indels for VAF
estimation.
It is shown from WGS that there are typically tens to
hundreds of somatic SVs in a genomically instable colo-
rectal or breast cancer genome [12-14]. Potentially more
exist at sub-clonal levels in a heterogeneous sample [15].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2105/15/299Therefore, enabling VAF estimation of SVs can substan-
tially impact mutational profiling and tumor heterogen-
eity analysis.
Unfortunately, it is not straightforward to quantify the
amount of evidences that is specifically associated with
an SV allele from sequence alignments, which are usu-
ally obtained from aligning individual reads or read pairs
to the human reference genome [16]. Depending on the
type of SV and the results of alignment, signals that indi-
cate the presence of an SV may appear in several differ-
ent forms such as read depth, discordant read pairing,
read split-alignment, end-clipping, unmapped read and
so on [17]. Many tools only utilize one form of signal
[18]. For example, THetA [19] and ABSOLUTE [7]
utilize only read depth (or counts) from large (Mega-
base) copy number variants (CNVs). Thus, they cannot
be applied to estimate the allele fraction of balanced SVs
such as inversions and reciprocal translocations. They
are also limited in measuring smaller SVs, which often
occur more frequently than larger SVs. BreakDancer [20]
utilizes only discordant read pairs, while CREST [21]
and Pindel [22] utilize only split-reads. Several recent
tools such as GenomeSTRiP [23], Delly [24] and ERDS
[25] utilize two or more signals. However, they do not
have an integrative model that simultaneously explains
multiple forms of signals introduced by an SV and are
geared towards identifying discrete SV genotypes in nor-
mal diploid genomes. CloneHD [26] utilized both SNVs
and CNVs in a hierarchical model for probabilistic infer-
ence, but it did not utilize other types of SVs. To our
best knowledge, no method has been proposed to esti-
mate continuous VAF for SVs in heterogeneous tumor
samples.
We present in this paper, a maximum-likelihood
method and a software tool called BreakDown that aim
to address the aforementioned challenges in estimating
VAF for SV in a heterogeneous tumor sample. Our
method analytically integrates 3 forms of SV signals: read
depth, discordant read pairing and end-clipping and thus
considers more evidences than any existing tools. Our
formulation expands beyond existing work that assumes
monoclonality and allows us to include any SVs in clonal
heterogeneity inference, an improvement over previous
investigations that involved only SNVs (e.g., Pyclone [8],
Sciclone [27] and ExPANDs [28]) or large CNVs. As a
stand-alone tool, BreakDown can be applied in a NGS
data analysis pipeline to enhance the accuracy and esti-
mate VAFs for SVs nominated by any other discovery
tools. We assessed the performance of BreakDown using
both simulated and real cancer genome sequencing data
and found that it can produce consistently satisfactory
results. BreakDown was designed to be self-adaptive to
different conditions (e.g., coverage, read length, etc.),
normalized against biases (e.g., GC content), and robustto outliers. It builds in a scoring system that is calibrated
with validation data and can accurately inform true error
probabilities.
Results
A maximum likelihood VAF estimator
We have developed an approach using maximum likeli-
hood, which estimates the VAF of an SV that best
explains the associated alignment data. Briefly, our ap-
proach includes the following five steps (Figure 1, see
Methods for details). First, parameters such as average
coverage and insert size are initialized based on mea-
sures from randomly selected regions of the genome.
Read pairs encompassing an SV are extracted from the
data (usually in BAM format [29]) (Figure 1a). Second,
these read pairs are classified into three groups: A) nor-
mal, B) discordant and C) soft-clipped, based on their
alignment patterns. The numbers of read pairs n, d and
s are counted respectively in these 3 groups (Figure 1b-
c). These counts are normalized with respect to (w.r.t.)
GC content and mapping quality (Figure 1d). Third,
given the expected numbers of counts (Figure 1e) and
the observed counts n, d and s, the maximum likelihood
estimation of VAF and genotype can be obtained. VAF is
a continuous variable ranging between 0 and 1 and is
suitable to represent allelic structure in heterogeneous
samples, while genotype is a discrete variable (e.g., AA,
AB, and BB) that is suitable in homogeneous samples.
We keep both variables in one formulation to achieve
unified maximal likelihood inference in either heteroge-
neous or homogeneous samples (Figure 1f ). In this
paper, we focus on measuring VAFs in heterogeneous
tumor samples. A Bayesian variant score is computed to
quantify the confidence of the results (Figure 1g).
Based on the above method, we implemented a soft-
ware tool called BreakDown, which can be used in con-
junction with SV discovery tools such as BreakDancer,
GenomeSTRiP, Delly, CREST, Pindel, etc. to measure the
genotype or VAF of candidate SVs in a BAM file.
Characterizing the estimation accuracy
Our method involves sophisticated numerical calculations.
Does it always return the correct results? To answer this
question, we simulate read counts under various combina-
tions of parameters including VAFs, variant types, variant
sizes, sequence coverage, and insert sizes (Methods). We
then ask BreakDown to estimate VAFs from simulated
counts. To measure accuracy, we compute the chance of
an estimated VAF falling near (±10%) the true value in
1000 random trials.
From short-insert (500 bp) short-read (100 bp) low-
coverage (5×) data (Figure 2a), it is very challenging to es-
timate VAF accurately from SNPs, medium-size deletions




Figure 1 Schematic overview of BreakDown. a) In the input are the bam files and a set of SV calls. Reads encompassing each SV are extracted
for analysis. Genome-wide parameters such as average read count per bp per GC content are initialized. b) The encompassed reads are divided
into three groups: normal, discordant and soft-clipped. Reads in each group are counted. c) Normal reads for large CNVs are counted in a series
of consecutive non-overlapping bins. d) Read counts are normalized by GC contents. e) Expected read counts are defined as functions of SV, VAF
and sequencing data. f) Genotype and VAF that maximize the likelihood function are derived from the expected and observed read counts.
g) Variant scores are estimated that quantify the confidence of the results. Detailed explanations of the mathematics are available in Methods.
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estimate relatively high (≥0.1) VAF from large (1 Mb) dele-
tions. When coverage increases to 30X (Figure 2b), which
is typically for WGS data, VAF as low as 0.05 can be ac-
curately estimated from large deletions. Notably, VAF esti-
mated from INVs and TRAs are more accurate than those
estimated from SNVs, thanks to larger physical coverage
than sequence coverage. Medium-size deletions perform
always better than SNVs but worse than INVs and TRAs
in low (<0.2) VAFs. However it outperforms INVs and
TRAs at high (>0.3) VAFs. The accuracy of SVs over SNVs
becomes even more striking as the insert size becomes
longer (3 Kb) (Figure 2c), which indicates that our method
has successfully leveraged physical coverage. Even at ultra-
high (500×) coverage (Figure 2d), the SNVs still have
limited accuracy (<0.6) in estimating small (<0.1) VAFs
from short insert data. This result indicates that current
methods that measure VAFs from only SNVs are suffer-
ing from great challenges in delineating low-abundance
sub-clones, whereas when SVs are included, low-abundance sub-clones would have much higher chance
to be identified.
In summary, this simulation results indicate that our
method can accurately estimate VAFs for various types
of SVs and can enhance the heterogeneity analysis from
either short or long insert data at any coverage.
Comparison with published tools
The genomes of a tumor often evolve from a complex his-
tory that spans multiple years. To understand if Break-
Down is more accurate than other tools in inferring
complex history, we created a 5-clone mixture tumor
sample, based on a mock phylogeny tree (see Methods,
and Additional file 1: Figure S5). Each branch in the tree
represents the birth of a new clone that contains two
novel SVs. We generated synthetic reads from this bulk
tumor genome. We also generated additional reads from
the wild-type genome to simulate “normal contamination”
that are frequently observed in real tumor samples. We
created 6 data sets by varying the “normal contamination
Figure 2 Accuracy of estimated VAF in simulation. Plotted are the chances (Y axis) of the estimated VAF falling within 10% of the true VAF
(X axis). Each data point is estimated from 1000 random samples. Each subplot in the figure contains 4 curves representing the accuracy of VAFs
estimated from SNVs (red plus), 1 Kb deletions (green cross), 1 Mb deletions (blue triangle), and inversions/reciprocal-translocations (purple circle).
Various types of sequencing data are simulated and results compared: a) short-insert (500 bp) short-read (100 bp) at 5× sequence coverage,
b) short insert short read at 30× coverage, c) long insert (3000 bp) short read at 30x coverage and d) short insert short read at 500× coverage.
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both BreakDown and THetA on these 6 data sets and
compared the accuracy of estimated VAFs (Methods). In
all 6 sets, BreakDown achieved lower VAF estimation er-
rors than THetA (Figure 3, Additional file 2: Table S1).
We noticed that the accuracy of THetA starts to deterior-
ate when the normal contamination rate increases,
whereas BreakDown achieved consistently small errors
(<0.028). This result indicated that BreakDown is likely
more accurate in modeling real tumor sample that often
contain multiple tumor clones with variable rates of nor-
mal contamination.
Identify somatic SVs from tumor-normal matched WGS
data
To assess BreakDown’s capability in accurately estimat-
ing VAF and detecting somatic events in real data, we
download the WGS data of a metastatic melanoma can-
cer cell-line COLO-829 and its matched normal cell-line
[30]. For each putative SV, we compute its VAF in thetumor and the normal samples independently. We first
run BreakDown on 32 previously validated deletions in
the tumor [21,30]. Except for 5 events, which are sus-
pected to be germline (3 out of these 5 are also reported
as germline by CREST), the estimated VAFs in the nor-
mal sample for the other 27 events (see Additional file 3:
Table S2) have a mean of 0.024 and a standard deviation
of 0.032, as expected for somatic deletions.
In the tumor sample, we observe that those events on
chromosome 2, 3, 7, 17, 18, 20, 22 and X have VAFs diver-
ging from 0, 0.5 or 1, which are unexpected from a homo-
geneous diploid sample. This implies aneuploidy on these
chromosomes, assuming the tumor sample is pure. This
speculation is confirmed by a previous independent study
that characterizes the genome-wide copy number profile in
this sample [31]. On chromosomes 5, 10, 15 and 16 that
are indicated as mostly diploid [31], the estimated VAFs
are within 0.06 of either 0.5 or 1.0 (see Additional file 1:
Figure S3). Thus, the VAFs estimated by Breakdown in
both the tumor and the normal samples appear to be valid.
Figure 3 Comparison of VAF estimation errors between BreakDown and THetA. Plotted are the mean and the maximum errors (Y axis)
estimated from 10 lineage specific SVs by BreakDown and THetA under six normal contamination rates from 0 to 0.5 (X axis).
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samples independently, and run Breakdown on the
resulting deletion calls. Since previous studies have been
fairly comprehensive at identifying somatic heterozygous
deletions (gain-of-heterozygosity or GOH) we focus on
identifying loss-of-heterozygosity (LOH) events. We find
41 candidate LOH events that have VAFs between 0.45
and 0.55 in the normal and between 0 and 0.05 or 0.95
and 1 in the tumor (see Additional file 4: Table S3).
Among them, 40 (97.6%) overlap previously reported
LOH regions deriving from segmenting the B-allele
frequency of SNPs [30]. Two LOHs are of potential
functional impact. One at chr10q22.3 hits C10orf11, a
melanocyte-differentiation gene that has been related
with autosomal-recessive albinism in humans [32].
This homozygous deletion is found overlapping the
only homozygous region found in four affected indi-
viduals but not in any unaffected ones. The other LOH
at chr14q31.1 hits gene NRXN3 (Figure 4), which has
been related to malignant melanoma [33].
Identify sub-clonal SVs in breast cancer samples
We analyzed three pairs of matched tumor-normal
breast cancer samples to show that BreakDown can ac-
curately estimate VAFs of medium-size deletions, inver-
sions and translocations. The first pair consists of an
estrogen-receptor (ER)-positive primary breast cancer
sample PD4120, sequenced by Illumina Hi-seq at 188×,
and a matched normal sample at 38x. The clonal struc-
ture of this tumor has been previously inferred based on
SNVs and large CNVs [2,19,26]. The other two tumor
samples PD4115 and PD4088 were sequenced at around40× and their clonal structure have been characterized
by THetA [19]. For these 3 cases, we called structural
variation using BreakDancer on the paired tumor and
normal samples. We then run BreakDown on each of
the candidate SV calls. Through this process we discov-
ered several subclonal deletions (all of which are shorter
than 10 Kb), inversion and translocation (Table 1) that
have not been previously reported [34].
For the novel somatic SVs detected in PD4120, two
deletions (at chr5q14.3 and chr14q22.1) have Break-
Down predicted VAFs of 0.38 and 0.39, respectively (see
Additional file 1: Figure S4A and b). Because the tumor
purity of PD4120 is around 70% [2,19], these two dele-
tions are thereby likely heterozygous deletions in the pri-
mary clone (cluster D in [2]). The third deletion (at
chr10q25.3) (Figure 5a) has a predicted VAF of 0.12,
which may originate from one of the sub-clones (cluster
B in [2]) that has a SNV VAF peak at 0.11. It can be seen
(Figure 5a) that although the read depth signal is not ap-
parent, there are 15 discordant read pairs and 4 split
reads, all of which are important for estimating VAF but
have been ignored in the previous studies. The trans-
location (Figure 5b) has a BreakDown estimated VAF of
0.055, which matches another sub-clone (cluster A in
[2]) with a SNV VAF peak at 0.05. For the four deletions
discovered in PD4115 (76% tumor purity [19]), two (at
chr9q34.3 and chrXq13.2) have VAFs estimated at
around 0.4, which implies that they are likely heterozy-
gous variants in the founding clone. The other two (at
chr1p36.22 and chr9q31.2) had estimated VAFs at
around 0.3, and are likely homozygous deletions in the
subclone of 32.7% abundance [19]. One novel somatic
Figure 4 A loss-of-heterozygosity deletion in NRXN3 in COLO-829. Plotted is an image from the integrative genome viewer (IGV) that
represents read alignment over this deletion (chr14:79175898–79184805) in the tumor sample (top panel) and in the normal sample (bottom panel).
The discordant read pairs (dark-red bars connected by long grey lines) and drop in coverage (white space in the center) correspond to the start and
the end of the deletion (red horizontal bar). VAFs are estimated by BreakDown to be 1.0 and 0.49, respectively in the tumor and the normal.
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tumor purity [19]) has an estimated VAF 0.594, which
may be a homozygous event in the founding clone. In
summary, all of the novel somatic SVs we have identified
were consistent with previously inferred clonal architec-
ture, which demonstrated the accuracy of our method.Table 1 Novel sub-clonal somatic structural variants detected
SAMPLE CHR1 POS1 CHR2 POS2
PD4120 10 117351105 10 117352856
PD4120 5 86223184 5 86225988
PD4120 14 51889637 14 51896099
PD4120 22 19372768 22 21122617
PD4115 1 10151402 1 10152851
PD4115 9 108351356 9 108352767
PD4115 9 140773612 9 140777195
PD4115 X 73061886 X 73067477
PD4088 10 60908547 10 60920370
Listed are the novel somatic structural variants in the breast cancer sample PD4120
shown (column 8) are the genes overlapping with either deletion loci or translocatiDiscussion
In this paper, we presented a novel sequence analysis
method that can estimate the VAFs of SVs from a het-
erogeneous tumor sample.
We showed that VAFs estimated from SVs by our
methods are at least several times more accurate thanby BreakDown
TYPE Size(bp) GENE EST_VAF
Deletion 1751 ATRNL1 0.12
Deletion 2804 0.38
Deletion 6462 0.39
Translocation N/A HIRA, PI4KA 0.055
Deletion 1449 UBE4B 0.296
Deletion 1411 FKTN 0.285
Deletion 3583 CACNA1B 0.400
Deletion 5591 XIST 0.394
Inversion 11823 0.594




Figure 5 Sub-clonal SVs in PD4120. Plotted are the integrative genome viewer (IGV) screenshots that display reads in the tumor sample (top
panel) and in the normal sample (bottom panel) of a) A 1751 bp deletion between Chr10:117351105 and Chr10:117352856 with an estimated
tumor VAF 0.12, and b) an intra-chromosomal translocation between Chr22:19372768 and Chr22:21122617 with an estimated tumor VAF 0.055.
Reads are displayed from the top to the bottom in the following order: split reads (partially clipped bars), discordant read pairs (brown bars and
lines), and normal read pairs.
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diverse alignment signals (or coverage) from multiple
groups of reads. We also clearly demonstrated that dif-
ferent types of SVs are associated with different accuracy
in VAF estimation and our method can fully harness the
structural nature of these SVs.
Our work has extended current clonal inference from
SNVs and large CNVs to include medium-size SVs and
balanced SVs such as inversions and translocations. It is
possible to further extend our model to account for
complex SVs such as chromothripsis [35-37] and chro-
moplexy [38,39].In terms of accurately estimating VAFs, our approach
compared favorably to existing tools. In our simulation,
our model could more reliably estimate VAFs than THetA
from tumor samples that have multiple clones and a high
level of normal contamination. Other approaches such as
ABSOLUTE were not directly comparable to our ap-
proach, because they were designed to infer tumor purity
and ploidy without further characterizing clonal structure
or subclonal mutations [7].
In our analysis of COLO-829, we identified 40 putative
germline deletions in somatic LOH regions. These
events, although potentially important, have not been
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the same set of data. Therefore, the results obtained by
our approach can facilitate more accurate characterization
than the previous studies that utilized only SNVs and
indels [30]. Our finding also indicated that previous stud-
ies might have narrowly focused on detecting GOHs but
somewhat ignored LOHs. As medical genomics research
continues, we expect that our method will have a tremen-
dous opportunity to improve the comprehensiveness of
mutational profiling from an unprecedented amount of
WGS data that are accumulated by the tumor genome
atlas, the international cancer genome consortium [40]
and broader biomedical research communities.
The analysis of breast cancer samples PD4120, PD4115
and PD4088 demonstrated the identification of subclone
SVs using BreakDown. The estimated VAF, together with
those from SNVs and large CNVs, will serve as input to
further infer clonality, ploidy and purity. While these three
perspectives are intermingled, we believe that incorporat-
ing SVs into the picture [7,8,19,26] will greatly enhance
the quality of the inference.
Besides heterogeneous tumor samples, our method
can also be applied to infer the genotypes of normal
homogeneous WGS samples such as those in the 1000
genomes projects [41]. We will report our findings in a
separate manuscript.
Conclusions
We have developed a maximal likelihood framework,
which integrates multiple forms of alignment signals to
estimate the allele fraction of a structural variant. Our
methods and software tool BreakDown can estimate the al-
lele fraction of most structural variants including small and
large deletions, balanced inversions and translocations.
Evaluation based on both simulated and real data indicates
that our method outperforms existing approaches and can
greatly enhance the characterization of intra-tumoral het-
erogeneity in genomically instable tumors.
Methods
The Maximum Likelihood formulation
Our method starts from a NGS paired-end BAM file
produced by BWA [42] and a set of SV calls produced
by BreakDancer, Delly, Pindel and other SV discovery
tools. All these tools predict a start and an end coordi-
nates and the variant types such as deletion, duplication,
translocation and so on (Figure 1a).
The VAF or the genotype of a variant is determined by
maximizing the following likelihood function:
g; p½  ¼ argmax g;p½ L D g; pÞ;jð
where D denotes the alignment data in a window w that
encompasses the SV, and p the variant allele fraction(VAF) ranging from 0 to 1. In a monoclonal diploid
genome, we use g to represent genotypes (AA, AB, BB),
which are equivalent to p equals to 0, 0.5, and 1,
respectively. Including both p and g makes it conveni-
ent to apply our method to both heterogeneous and
homogeneous samples. The analytic form of the likeli-
hood function L is parameterized by read length r, in-
sert size t, average number of inserts (read pairs) per
bp c, which are estimated from normal diploid regions
of the genome.
BreakDown classifies read pairs into three groups
based on their alignment to the reference and counts
the numbers of: 1) normal read pair n, 2) discordant
read pair (DRP) d, and 3) soft-clipped reads (SR) s in w
(Figure 1b). The definitions of these read groups are
similar to previous work [17,43]. Soft-clipped reads are
recognized from the CIGAR strings in the BWA align-
ment (Figure 1b, [44]). We define a read pair as normal
if its two reads align with reference in expected orienta-
tion and distance, or otherwise as discordant.
An SV typically associates with three counts D = {n,d,s}.
However, for a balanced SV such as an inversion or a
reciprocal translocation, the normal counts are irrele-
vant: D = {d,s}. If an SV contains multiple breakpoints,
d and s each becomes an array of counts from constitu-
ent breakpoints.
Unlike other SV detection methods, which sequentially
analyze these different groups of reads [23-25], we jointly
analyze all the reads in w. Because read pairs in these 3
groups are sequenced and aligned independently, the likeli-
hood function can be expanded into the following product:
L ¼ P n pÞP d pÞP s pÞ;jðjðjð
which probabilistically integrates different types of counts.
In an unbiased shotgun sequencing experiment, these
counts should follow Poisson distributions with parameter
λ being defined in the following sections [45].
Modeling normal read pairs
An SV such as a copy number variant (CNV) can span a
very large genomic region with excessive GC content
variation. It is known that GC content can introduce
substantial sequencing bias and need to be normalized
against (see Additional file 1: Figure S1) [46]. In our
method, instead of having one normal count n from the
entire length of the encompassing window w, we split w
into smaller non-overlapping bins wi and count in each
bin the number of normal read pairs ni. We assume that
ni follows a Poisson distribution with
λni ¼ ci θð Þwi 1−pð Þ;
where ci is the average number of normal read pairs
per bp, normalized by the GC content in wi. We can
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domly selected regions in the genome (Figure 1d). wi has
a fixed width of 100 bp under our default setting. Splitting
a large window into small bins allows normalization being
performed at fine resolution and is particularly effective
for large SVs that span GC-content variable region. As an-
other corrective measure, we exclude bins that contain
more than 50% of zero mapping quality reads, an indica-
tor of potentially unreliable data that are introduced by
mapping errors in repetitive regions.
Modeling discordant read pairs
The expected count of DRP d should be linear to the
span coverage [47], i.e., insert size t minus twice read
length r (Figure 1b):
λd ¼ vdc θð Þ t−2rð Þp;
where c(θ) denotes the mean number of inserts per bp, a
function of the GC-content. The observed numbers of
DRPs often turn to be smaller than what is expected from
the span coverage due to simplification in the above defin-
ition and peculiarities of alignment algorithms. We used
vd, a trainable parameter ranging between 0 and 1 to com-
pensate such offset. In our experience, vd is around 0.8 in
typical WGS data (see Additional file 1: Figure S2).
Modeling soft-clipped read
The expected number of soft-clipped read s should be
proportional to the summation of read length (sequence
coverage) in a read pair (Figure 1b), assuming a read
would become soft-clipped if it has any overlap with the
breakpoint:
λs ¼ vsc θð Þ2rp:
This formulation is approximate because an aligner
may choose not to soft-clip a read when it only slightly
overlaps the breakpoint. Sometimes, an aligner may in-
correctly soft-clip a non-breakpoint containing read.
However, such aligner-specific behaviors can hardly be
modeled post-alignment. To alleviate this bias, we use a
trainable parameter vs to compensate for such offset. In
our experience, vs is around 0.7 in typical WGS data
(Additional file 1: Figure S2).
VAF estimation
Taken together, we can now express the likelihood func-
tion as
L ¼ f Pois d; λdð Þ⋅f Pois s; λsð Þ⋅Πmi¼1f Pois ni; λnið Þ;
where m denotes the number of bins for counting nor-
mal read pairs (Figure 1c). For genomes sequenced with
multiple DNA libraries, the quantities estimated from
each library are combined through multiplication,assuming that the libraries are independently con-
structed. Without loss of generalizability, we present the
derivation of VAF from a single library.
Solving equation dL/dp = 0 yields the variant allele

















C ¼ d þ s
Confidence scoring
We use variant score (VarScore) to quantify error prob-
ability, i.e., the chance that there is no SV at the input
site (Figure 1g):
SV ¼ −10 log10 P p ¼ 0 DÞÞ;jðð
where P(p = 0|D) represents the posterior probability
that VAF equals to 0 given the data. For practical imple-
mentation, we used discretized genotype to estimate the
error probabilities:
SV ¼ −10 log10 P g ¼ AA DÞÞjðð
where P(g =AA|D) is the posterior probability that the
genotype is homozygous reference. We can calculate this
quantity based on Bayesian Theorem:





where PV(G) is the prior variant probability of genotype G
and Gl, l = 0, 1, or 2 represents homozygous reference,
heterozygous variant and homozygous variant genotypes,
respectively. For a heterogeneous tumor sample, uniform
genotype prior is assumed PV(G) =1. For a homogeneous
normal sample, the genotype prior can be defined based
on population genetics [23]. Assuming Hardy-Weinberg
equilibrium,
PV Glð Þ ¼
1−qð Þ2; l ¼ 0
2q 1−qð Þ; l ¼ 1




where q is the average allele frequency of the SVs in the
population.
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Parameters that are needed by our model are initialized
from the data before they are applied to VAF estima-
tion. We randomly choose N (N=10 by default) 10 Mb
regions from the BAM file (excluding centromere and
telomere regions). We estimate median read length r,
insert size t from the data. We create a lookup table
that stores average read pair per bp ci(θ) as a function
of GC content (an integer ranging from 0 to 100) (see
Additional file 1: Figure S1).
Simulation
To examine the accuracy and robustness of our max-
imum likelihood estimators and to characterize different
parameters, we simulated a set of read counts for SNPs,
deletions (with size 1K and 1M bp), inversions or recip-
rocal translocations at coverages of 5X, 30X and 500X
based on short insert size (500 bp) and short read length
(100 bp). We also simulated read counts from long in-
sert size (3000 bp) and short read length (100 bp) at 30X
coverage (Figure 2c).
For each parameterization, we randomly sampled 1000
data points from the Poisson distributions (as described
previously). For SNVs, we assumed that the number of
variant supporting reads follows a binomial distribution
parameterized by the given coverage and VAF. For an
inversion or a reciprocal translocation that have two
breakpoints, counts at each breakpoint were simulated
independently.
Comparison with THetA
We simulated five alterative copies of chromosome 20
(chr20), each containing unique SVs, as represented on
the leaf nodes of a phylogeny tree (see Additional file 1:
Figure S5). Each of the five clones contains two or four
randomly placed non-overlapping 1.5 Mb heterozygous
deletions or one-copy tandem duplications. Each clone
makes up to a fraction of the total tumor mass. We used
wgsim to simulate reads from each chr20 sequences.
The corresponding coverages are calculated according to
their clonal fraction and the normal contamination rate,
which equaled to 0, 0.1, 0.2, 0.3, 0.4 or 0.5 in our simula-
tion. The total coverage was kept at a constant 50X
across all conditions. All the deletions and the duplica-
tions were simulated as single copy alterations, and
therefore the true VAF ranged from 0.05 to 0.3 when the
normal contamination rate is 0. When the normal con-
tamination rate is 0.5, the true VAFs ranged from 0.025
to 0.15. We mapped the synthetic reads to the wide-type
chr20 reference using bwa-mem [42].
We ran THetA beta version 0.60 under default param-
eters. The whole chr20 was segmented into 19 regions,
corresponding to 10 non-overlapping copy number al-
terations with copy number neutral regions in between.The interval count file, serving as input to THetA, was
generated by counting reads aligned into each of the 19
regions, for both the tumor and the normal samples.
This version of THetA supported the inference of up to
3 clones. However, it reported that n=3 was not a good
model for this data. Therefore, all the results we re-
ported from THetA are based on n=2, i.e., one tumor
clone plus one contaminating normal clone. Since the
maximum copy number THetA estimated was 3, we
converted copy number of those 10 intervals into VAF
by Ci−2j j2  1−μð Þ, in which Ci represents the copy number
estimated for the i th interval, and μ the estimated nor-
mal contamination rate.
Data
COLO-829 NGS data was downloaded from the European
Genome-Phenome Archive (Accession number: EGAD00
000000055). CREST and validated call set was from
Additional file 3: Table S2 (nmeth.1628-S2) downloaded
from [21]. The LOH set was obtained from the Supple-
mentary Table six from [30].
The NGS data for the breast cancer samples were down-
loaded from the European Genome-Phenome Archive
(Accession number: EGAD00001000138). Validated SV set
was obtained from Supplementary Table one from [34].
Software availability
The BreakDown source code and manual are available
for download at [48].
Additional files
Additional file 1: Figure S1. GC content biases in read counts.
Figure S2. Comparison between the observed and the expected read
counts. Figure S3. Plots of estimated VAF of validated deletions. Figure S4.
Plots of two novel somatic deletions identified from the breast cancer
sample. Figure S5. A mock phylogeny tree of a polyclonal tumor mass.
Additional file 2: Table S1. Comparison of the VAF estimation errors
between BreakDown and THetA based on simulation.
Additional file 3: Table S2. A list of 32 previously reported deletions
with BreakDown estimated VAFs in COLO-829.
Additional file 4: Table S3. A list of 41 LOH deletions detected by
BreakDown in COLO-829.
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